Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

DiaMedica Therapeutics (DMAC) Interest & Investment Income (2024 - 2026)

DiaMedica Therapeutics filings provide 3 years of Interest & Investment Income readings, the most recent being $470000.0 for Q1 2026.

  • Quarterly Interest & Investment Income rose 5.86% to $470000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Mar 2026, down 20.39% year-over-year, with the annual reading at $1.7 million for FY2025, 27.47% down from the prior year.
  • Interest & Investment Income hit $470000.0 in Q1 2026 for DiaMedica Therapeutics, roughly flat from $472000.0 in the prior quarter.
  • Across five years, Interest & Investment Income topped out at $618000.0 in Q3 2024 and bottomed at $313000.0 in Q2 2025.
  • Average Interest & Investment Income over 3 years is $493333.3, with a median of $472000.0 recorded in 2025.
  • The largest annual shift saw Interest & Investment Income plummeted 40.27% in 2025 before it rose 5.86% in 2026.
  • DiaMedica Therapeutics' Interest & Investment Income stood at $543000.0 in 2024, then dropped by 13.08% to $472000.0 in 2025, then decreased by 0.42% to $470000.0 in 2026.
  • Per Business Quant, the three most recent readings for DMAC's Interest & Investment Income are $470000.0 (Q1 2026), $472000.0 (Q4 2025), and $440000.0 (Q3 2025).